Neola Medical

Neola Medical ROCE

The Return on Capital Employed (ROCE) of Neola Medical (NEOLA.ST) as of Oct 25, 2026 is -14.69 %. In the previous year, Return on Capital Employed (ROCE) was -16.04 % — a change of -8.40% (higher).

ROCE

-14.69 %

YoY

-8.40%

Last updated:

In 2025, Neola Medical's return on capital employed (ROCE) was -14.69 %, a -8.40% increase from the -16.04 % ROCE in the previous year.

The Neola Medical ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-9.51 SEK
Jan 1, 2019
-29.49 SEK
Jan 1, 2020
-33.35 SEK
Jan 1, 2021
-18.10 SEK
Jan 1, 2022
-15.40 SEK
Jan 1, 2023
-12.17 SEK
Jan 1, 2024
-16.04 SEK
Jan 1, 2025
-14.69 SEK
The Neola Medical ROCE history
YEARROCEYoY
-14.69 %-8.40%
-16.04 %+31.76%
-12.17 %-20.96%
-15.40 %-14.92%
-18.10 %-45.71%
-33.35 %+13.08%
-29.49 %+210.22%
-9.51 %-74.62%
-37.46 %+66.20%
-22.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neola Medical Stock analysis

What does Neola Medical do? Neola Medical AB commercializes medical devices based on its patented GASMAS technology for continuous lung monitoring in premature babies. The company's primary product, NEOLA, provides real-time alerts for life-threatening complications by measuring lung volume changes and oxygen concentration. Neola Medical targets neonatal intensive care units as its key market segment, serving healthcare providers who require advanced monitoring solutions for premature infants. The firm's revenue model relies on selling the NEOLA device and associated technology to hospitals and medical facilities specializing in neonatal care. The company's business concept centers on the commercialization of its medical technology product for continuous lung monitoring, leveraging the GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical focuses on the neonatal intensive care market segment, where its device offers continuous monitoring capabilities that address critical needs in premature infant care. The primary purpose of the NEOLA device is to support neonatal intensive care through real-time monitoring and alerts for complications. Neola Medical AB's revenue streams come from the sale of the NEOLA medical device and its underlying technology to healthcare institutions. The company targets neonatal intensive care units as its primary customer segment, focusing on hospitals and medical facilities that provide specialized care for premature babies. The firm's business model is built around the commercialization of its patented GASMAS technology through the NEOLA device, which addresses specific monitoring needs in neonatal care. Neola Medical is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Neola Medical's Return on Capital Employed (ROCE)

Neola Medical's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Neola Medical's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Neola Medical's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Neola Medical’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Neola Medical stock

Return on Capital Employed (ROCE) of Neola Medical is -14.69 % in 2025.

Return on Capital Employed (ROCE) of Neola Medical changed from -16.04 % to -14.69 %, representing a -8.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Neola Medical since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Neola Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Neola Medical

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Neola Medical